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we tested the effects of a single extra-copy of p53 on the function of CPCs in the presence of oxidative stress me-
diated by doxorubicin in vitro and type-1 diabetes in vivo. CPCs were obtained from super-p53 transgenic mice
(p53-tg), inwhich the additional allele is regulated in amanner similar to the endogenous protein. Old CPCswith
increased p53 dosage showed a superior ability to sustain oxidative stress, repair DNA damage and restore cell
division. With doxorubicin, a larger fraction of CPCs carrying an extra-copy of the p53 allele recruited γH2A.X
reestablishing DNA integrity. Enhanced p53 expression resulted in a superior tolerance to oxidative stress in
vivo by providing CPCs with defense mechanisms necessary to survive in the milieu of the diabetic heart; they
engrafted in regions of tissue injury and in three days acquired the cardiomyocyte phenotype. The biological ad-
vantage provided by the increased dosage of p53 in CPCs suggests that this genetic strategy may be translated to
humans to increase cellular engraftment and growth, critical determinants of successful cell therapy for the fail-
ing heart.





Stem cell fate1. Introduction
Myocardial aging in animals and humans is characterized by an in-
crease in number of resident cardiac progenitor cells (CPCs) expressing
the senescence-associated protein p16INK4a, which prevents perma-
nently the reentry of stem cells into the cell cycle (Beausejour and
Campisi, 2006; Dimmeler and Leri, 2008; Sanada et al., 2014; Leri et
al., 2015). This age-dependent effect results in a reduction of the pool
of functionally-competent CPCs in the old heart (Torella et al., 2004). Al-
terations of coronary blood flow and defects in the structural determi-
nants of tissue oxygenation in the aging myocardium (Hachamovitch
et al., 1989) create hypoxic micro-domains where CPCs are maintained
in a quiescent state (Sanada et al., 2014), impairing the activation of aA damage response; WT, wild
ouse; Aogen, angiotensinogen;
population doubling time; ROS,
undation, Swiss Institute for
gano, Switzerland.
i).
. This is an open access article undercompartment of progenitor cells with relatively intact replicative
reserve.
The tumor suppressor p53 is amajor regulator of DNA repair and cell
division, cellular aging and apoptosis (Riley et al., 2008). Phosphoryla-
tion of the N-terminal of p53 promotes DNA repair, a process that is in-
timately linked to the progression of the cell cycle. DNA repair may be
less effective in old CPCs, resulting in the accumulation of DNA lesions,
a phenomenon that favors cellular senescence. The expression of p53
increases with aging and heart failure (Leri et al., 2003; Cheng et al.,
2013) but its actual role in CPCs is unknown; p53may trigger apoptosis
of old cells and may induce DNA repair in cells with a younger pheno-
type (Matheu et al., 2007).
Whether this potential youth promoting effect of p53 is determined
by a successful DNA damage response (DDR), mediated by transient
reparable DNA lesions in the telomeric and non-telomeric regions of
the genome, remains to be defined. A prolonged DDR signaling may re-
sult in the accumulation of non-reparable DNA foci and initiation of cell
death (Fumagalli et al., 2012). Moreover, these intrinsic variables of
CPCs have implications in the outcome of cell therapy for the damaged
heart, where the unfavorable conditions of the recipient myocardium
with high levels of oxidative stress affect the survival and growth of
the delivered cells. These questions have been addressed in the presentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and then by assessing CPC engraftment in the diabetic heart that is char-
acterized by an environment inwhich the generation of reactive oxygen
and inflammation condition its evolution (Rota et al., 2006).
The super-p53 mouse (p53-tg) (Garcia-Cao et al., 2002), which is
based on a C57BL/6J genetic background, carries a single extra gene-
dose of p53. This single-copy transgene is regulated in a manner similar
to its endogenous counterpart; p53 is not constitutively active, but un-
dergoes post-translational modifications in response to stress stimuli,
resulting in a moderately higher p53 activity (Garcia-Cao et al., 2006).
The increased gene dosage of p53 triggers an amplified DDR in lympho-
cytes, splenocytes, embryonic fibroblasts, and epithelial cells of the skin
and intestine (Garcia-Cao et al., 2002), but its impact on CPC aging and
growth reserve has never been determined. Because of these character-
istics, this animal model was considered relevant for understanding the
role of p53 in CPC function with aging and oxidative stress.
2. Methods
2.1. Animals
All procedures were approved by the Institutional Animal Care and
Use Committee of the BrighamandWomen'sHospital. Animals received
humane care in compliancewith the “Guide for the Care andUse of Lab-
oratory Animals” as described by the Institute of Laboratory Animal Re-
search Resources, Commission on Life Sciences, National Research
Council. Male and female wild-type (WT) and super p53 transgenic
(p53-tg) mice in a C57BL/6 genetic background were studied
(Garcia-Cao et al., 2002, 2006).WT and p53-tg at different ageswere in-
cluded in the protocols.
2.2. Ventricular Hemodynamics
Cardiac function was measured in young-adult, 3–6 months of age,
and old, 24–31 months of age, WT and p53-tg mice. Left ventricular
(LV) parameters (Leri et al., 2003; Torella et al., 2004; Rota et al.,
2007; Sanada et al., 2014)were obtained in the closed chest preparation
with a MPVS-400 system for small animals (Millar Instruments)
equipped with a PVR-1045 catheter. Under sodium pentobarbital
(50mg/kg bodyweight, i.p.) anesthesia, the right carotid artery was ex-
posed and the pressure transducer was inserted in the carotid artery
and advanced into the LV cavity. Data were acquired and analyzed
with Chart 5 (ADInstruments) software.
2.3. Myocyte Isolation
Under pentobarbital anesthesia, the heart was excised and LV
myocytes were enzymatically dissociated (Torella et al., 2004; Rota et
al., 2007; Signore et al., 2015). Briefly, the myocardium was perfused
retrogradely through the aorta at 37 °Cwith a Ca2+-free solution gassed
with 85% O2 and 15% N2. After 5 min, 0.1 mM CaCl2, 274 units/ml colla-
genase (type 2,Worthington Biochemical Corp.) and 0.57 units/ml pro-
tease (type XIV, Sigma) were added to the solution which contained
(mM): NaCl 126, KCl 4.4, MgCl2 5, HEPES 20, Glucose 22, Taurine 20,
Creatine 5, Na Pyruvate 5 and NaH2PO4 5 (pH 7.4, adjusted with
NaOH). At completion of digestion, the LV was cut in small pieces and
re-suspended in Ca2+ 0.1mM solution. Myocytes were collected by dif-
ferential centrifugation.
2.4. Ca2+ Transients and Sarcomere Shortening
Isolated LV myocytes were placed in a bath on the stage of an
Axiovert Zeiss Microscope and IX71 Olympus inverted microscope for
the measurements of contractility and Ca2+ transients. Experiments
were conducted at room temperature. Cells were bathed continuously
with a Tyrode solution containing (mM): NaCl 140, KCl 5.4, MgCl2 1,HEPES 5, Glucose 5.5 and CaCl2 1.0 (pH 7.4, adjusted with NaOH). Mea-
surements were performed in field-stimulated cells by using IonOptix
fluorescence and contractility systems (IonOptix, Milton, MA). Contrac-
tions were elicited by rectangular depolarizing pulses, 2 ms in duration,
and twice-diastolic threshold in intensity, by platinum electrodes
(Torella et al., 2004; Signore et al., 2015). Changes in mean sarcomere
length were computed by determining the mean frequency of sarco-
mere spacing by fast Fourier transform and then frequency data were
converted to length. Ca2+ transients weremeasured by epifluorescence
after loading the myocytes with 10 μM Fluo-3 AM (Invitrogen). Excita-
tion length was 480 nm with emission collected at 535 nm using a
40× oil objective. Fluo-3 signals were expressed as normalized fluores-
cence (F/F0).
2.5. Immunohistochemistry
Following the acquisition of the hemodynamic parameters, the ab-
dominal aorta was cannulated with a polyethylene catheter, PE-50,
filled with a phosphate buffer, 0.2 M, pH 7.4, and heparin, 100 U/ml. In
rapid succession, the heart was arrested in diastole by the injection of
0.15 ml of CdCl2, 100 mM, through the aortic catheter, the thorax was
opened, perfusion with phosphate buffer was started, and the vena
cava was cut to allow drainage of blood and perfusate. After perfusion
with phosphate buffer for 2min, the coronary vasculature was perfused
for 15 min with formalin. Subsequently, the heart was excised and em-
bedded in paraffin (Leri et al., 2003; Torella et al., 2004; Rota et al., 2007;
Sanada et al., 2014).
Formalin-fixed paraffin-embedded myocardial sections were la-
beled with goat polyclonal anti-c-kit (R&D: cat. no. AF1356), mouse
monoclonal anti-α-sarcomeric actin (Sigma-Aldrich: clone 5C5, cat.
no. A2172) to identify CPCs and cardiomyocytes, respectively. Nuclei
were stained by DAPI. Cycling CPCs and cardiomyocytes were recog-
nized by labeling with mouse monoclonal anti-Ki67 antibody (BD Bio-
sciences: cat. no. 550609). Apoptotic and senescent cells were
recognized by the TUNEL assay (Roche: cat. no. 11684795910) and
p16INK4a localization (Cell Signaling: cat. no. 4824), respectively (Leri
et al., 2003; Torella et al., 2004; Rota et al., 2007; Sanada et al., 2014).
The number of c-kit-positive CPCs per unit area of myocardium in the
atria and LV mid-region was determined as previously described
(Torella et al., 2004; Sanada et al., 2014).
2.6. Western Blotting of Cardiomyocytes
Protein lysates of cardiomyocytes were obtained using RIPA buffer
(Sigma) and protease inhibitors. Equivalents of 50 μg of proteins were
separated on 10–12% SDS-PAGE, transferred onto PVDF membranes
(Bio-Rad) and subjected to Western blotting with mouse monoclonal
anti-Aogen (Swant: cat. no. 138), rabbit polyclonal anti-AT1R
(Millipore: cat. no. 15552), rabbit polyclonal anti-Bax (Cell Signaling:
cat. no. 7074) and rabbit polyclonal anti-Bcl2 (Cell Signaling: cat. no.
D17C4) diluted 1:500–1000 in TBST or BSA overnight at 4 °C. HRP-con-
jugated anti-IgG were used as secondary antibodies. Proteins were de-
tected by chemiluminescence (SuperSignal West Femto Maximum
Sensitivity Substrate, Thermo Scientific: cat. no. 34095) and optical den-
sity was measured. Loading conditions were determined by Ponceau S
(Sigma) staining of the membrane after transfer. Lung and kidney
were used as positive controls for Aogen and AT1R, respectively. SVT2
and B16 melanoma cells were employed for the recognition of the
bands corresponding to Bax and Bcl2, respectively (Leri et al., 1998;
Torella et al., 2004; Goichberg et al., 2013).
2.7. CPC Isolation and Expansion
Following myocyte isolation, the small cardiac cell pool present in
the supernatant was plated in Petri dishes and, 24 h later, c-kit positive
cells were obtained by immunomagnetic sorting (Miltenyi Biotec.: cat.
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Sanada et al., 2014). Subsequently, c-kit-positive cells were cultured in
F12K medium supplemented with 10% fetal bovine serum.
Immunomagnetic sorting for c-kit was repeated every three passages
to select with this protocol the fraction of cells that retained c-kit ex-
pression. This approach was required because mouse c-kit-positive
CPCs tend to lose this surface receptor with time in culture. When pos-
sible, immediately sorted cells were utilized; however, assays requiring
large numbers of CPCs were conducted after cell expansion.
2.8. Population Doubling Time (PDT)
CPCs were plated at low density. The number of cells per unit area
was determined at the time of seeding and 24 h later (D'Amario et al.,
2011, 2014). PDT was computed by linear regression of log2 values of
cell number.
2.9. Proliferation, Senescence and Apoptosis
These cellular parametersweremeasured in baseline conditions, fol-
lowing exposure to doxorubicin (Doxo; 0.5 μM) for 4 h, and 24, 48 and
72 h following removal of Doxo. Cells were fixed in 4% paraformalde-
hyde and the fraction of cycling cells was determined by
immunolabeling for Ki67 (eBioscience: cat. no. 14-5698-82, RRID: AB_
10854564) and confocal microscopy (D'Amario et al., 2011, 2014;
Goichberg et al., 2013). The fraction of cells that reached replicative se-
nescence and irreversible growth arrest was evaluated by the expres-
sion of the senescence-associated protein p16INK4a (Abcam: cat no.
ab16123, RRID: AB_302274) (D'Amario et al., 2011, 2014; Goichberg
et al., 2013). Apoptosis was measured in CPCs at baseline and following
exposure to Doxowith the Annexin V detection assay (BD Pharmingen).
Annexin V binds to the phosphatidylserine exposed on the outer leaflet
of the cell membrane during apoptotic cell death. CPCs were seeded in
96 multi-well clear bottom black plates (3603, Corning); 24 h later,
the medium was removed and cells were washed with PBS. FITC-
Annexin V (556547, Pharmingen) diluted in binding buffer provided
by the manufacturer was then added to the wells for a period of
30 min. After washing in PBS, cells were stained with DAPI. FITC (Exci-
tation 490 nm; Emission 525 nm) and DAPI (Excitation 358 nm; Emis-
sion 461 nm) signals were quantified using Perkin Elmer EnVision
Multilabel Reader. Apoptosis was calculated by normalizing the FITC
signal to the number of cells represented by the DAPI signal.
2.10. DDR Foci and Comet Assay
CPCs were stained with a mouse anti-phospho-histone H2A.X
(Ser139) (Millipore: cat. no. 05-636, RRID: AB_309864). Imaris software
spot module was employed for the recognition of the γH2A.X-positive
DDR foci and 3D rendering of the data (Goichberg et al., 2013). The
number of foci per nucleus was counted utilizing the Imaris software.
The comet assay was performed utilizing the OxiSelect Comet Assay
Kit (Cell Biolabs: cat. no. STA-351). Cells were embedded in agarose gel
and placed on top of a microscope slide. Slides were treated with alka-
line lysis buffer to remove proteins and, subsequently, immersed in TE
buffer. Electrophoresis was performed to induce the formation of
comets. Slides were stained with Vista green dye and analyzed by fluo-
rescence microscopy (Lorenzo et al., 2013). The distance between the
center of the head and the center of the tail, i.e. the tail moment length,
was measured with ImageJ using comet assay plug-in. The tail moment
was then calculated by the product of the percentage of damaged DNA
and the tail moment length.
2.11. Western Blotting of CPCs
Protein lysates of CPCs were obtained using RIPA buffer (Sigma-Al-
drich: cat. no. R0278) and protease inhibitors (Torella et al., 2004;Goichberg et al., 2013). Equivalents of 10 μg proteins were separated
on 4–20% SDS-PAGE and subjected to traditional Western blotting. Ad-
ditionally, equivalents of 1 μg proteins were analyzed with
ProteinSimple Wes automated Western blotting system (Harris,
2015). The following antibodies were utilized: mouse monoclonal
anti-p53 (Cell Signaling), rabbit polyclonal anti-p53 (Ser 37) (Cell Sig-
naling Technology: cat. no. 2524, RRID: AB_331743), rabbit polyclonal
anti-p53 (Ser15) (Cell Signaling Technology: cat. no. 9286S, RRID: AB_
331741) andmousemonoclonal anti-p16INK4a (Cell Signaling Technolo-
gy: cat. no. 8884S, RRID: AB_11129865). Loading conditionswere deter-
mined by GAPDH.2.12. qRT-PCR
Total RNAwas extracted fromCPCswith TRIzol Reagent (Invitrogen:
cat. no. 15596018) and employed for the measurement of the quantity
of transcripts of p53, Mdm2, Puma, Noxa, PIDD, Trp53inp, p16INK4a,
p21Cip1, IGF-1 and PCNA. cDNA for mRNAs was obtained from 2 μg
total RNA in a 20 μl reaction using High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems: cat. no. 4368814) and 100 pmole of
oligo(dT)15 primer (Hosoda et al., 2009; Goichberg et al., 2013). This
mixture was incubated at 37 °C for 2 h. Quantitative RT-PCR was per-
formed with primers designed using the Vector NTI (Invitrogen) soft-
ware or downloaded from the NIH qdepot mouse primer database
(for sequences see Supplementary Methods). StepOnePlus Real-Time
PCR system (Applied Biosystems) was employed. cDNA synthesized
from 100 ng total RNAwas combinedwith Power SYBR Green PCRMas-
ter Mix (Applied Biosystems: cat. no. 4367659) and 0.5 μM each of for-
ward and reverse primers. Cycling conditions were as follows: 95 °C for
10 min followed by 40 cycles of amplification (95 °C denaturation for
15 s, and 60 °C annealing-extension for 1 min). The melting curve was
then obtained. To avoid the influence of genomic contamination, for-
ward and reverse primers for each gene were located in different
exons. Reactionswith primers alonewere also included as negative con-
trols. Quantified values were normalized against the input determined
by the housekeeping gene β2-microglobulin. Real-time PCR products
were run on 2% agarose/1X TBE gel.2.13. Diabetes and CPC Injection
C57Bl/6 female mice at 3–4 months of age were treated with
streptozotocin (STZ, Sigma) for 7 consecutive days (~100 mg/kg body
weight per day, i.p.) (Rota et al., 2006). STZ was dissolved in 0.9% saline
solution containing 20mM/l sodium citrate tribasic dehydrate (Sigma).
Final STZ concentration was 5 mg/l. Animals developed hyperglycemia
~2 weeks after the last injection of STZ. TRUEtrack meter (Home Diag-
nostics, Inc.) and test strips were employed to measure blood glucose.
Animals with blood glucose level N 400 mg/dl were included in the
study.
Three–four weeks after the onset of hyperglycemia, 200,000 CPCs
were injected within the myocardium (4 injections of 5 μl each). Mice
were sacrificed 3 days following cell transplantation. Hearts were per-
fused with formalin and embedded in paraffin as described above. Tis-
sue sections obtained from the mid-portion of the LV were stained for
GFP (rabbit polyclonal anti-GFP, Molecular Probes: cat. no. A-11122,
RRID: AB_221569; chicken polyclonal anti-GFP, Abcam: ab13970,
RRID: AB_300798), α-sarcomeric actin (mouse anti-α-sarcomeric
actin IgM, Sigma-Aldrich: cat. no. A2172, RRID: AB_476695), GATA4
(rabbit polyclonal anti-GATA4, Abcam: cat. no. ab84593, RRID: AB_
10670538) and troponin I (mouse monoclonal anti-troponin I, Abcam:
cat. no. ab10231, RRID: AB_296967). The number of GFP-positive cells
per 10 mm2 of myocardium was measured throughout the entire
cross-section of the LV.
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Data are presented asmean±SD. The Shapiro-Wilk testwas utilized
to define the normality of value distribution. In case of normal distribu-
tion, significance between two groups was determined by unpaired
two-tailed Student's t-test. For multiple comparisons, the ANOVA test
with the Bonferroni parametric correction was employed. When the
normality test failed, the Mann-Whitney Rank Sum Test and the
Kruskal-Wallis One Way ANOVA were employed. In all cases, p b 0.05
was considered significant (McDonald, 2014).
3. Results
3.1. p53 Does Not Alter the Mechanical and Growth Properties of
Cardiomyocytes
The overexpression of p53 results in premature organism aging and
animal mortality (Serrano and Blasco, 2007). The shorter lifespan may
be due to defects in cardiac performance andmyocyte mechanics, com-
monly found in the old failing heart (Leri et al., 2003; Torella et al., 2004;
Signore et al., 2015). Therefore, we determined whether an increase inFig. 1.Aging and p53 do not alter cardiac andmyocyte function. (a) Hemodynamics in young-ad
p53-tg, n = 7; old WT, n= 11, old p53-tg, n= 6). LV SP, LV systolic pressure; LV EndDP, LV en
shortening of cardiomyocytes in youngWT (n=112 cells from 10mice) and young p53-tg (n=
in old WT (n = 40 cells from 3 mice) and old p53-tg (n = 25 cells from 3 mice).p53 gene dosage had a negative effect on ventricular hemodynamics
and the electro-mechanical properties of cardiomyocytes. Wild-type
(WT) and p53-tg mice at 3–6 and 24–31 months of age were studied.
At both ages, left ventricular (LV) systolic pressure, LV end-diastolic
pressure, LV developed pressure, and LV +dP/dt and −dP/dt did not
differ in p53-tg and WT mice (Fig. 1a).
Moreover, Ca2+ transient amplitude, sarcomere shortening, and the
timing parameters of Ca2+ transient and sarcomere shortening were
measured in isolated LV myocytes. In all cases, no differences were
found (Fig. 1b, c), suggesting that the physiological properties of the
LV and cardiomyocytes were preserved in WT mice as a function of
age, and a single extra gene-dose of p53 did not alter the function of
the old heart. These observations are consistent with previous results
in which aging effects have not been detected in WT 26 month-old
C57BL/6J mice (Sanada et al., 2014).
To define further the characteristics of cardiomyocytes, the degree of
cell replication and death was evaluated in young-adult, 8–11 months,
and old, 20–25 months, WT and p53-tg mice. The fraction of cycling
Ki67-positive myocytes and the percentage of apoptotic myocytes
were similar in young WT and p53-tg and increased equally with age
in both groups of mice (Fig. 2a, b). However, only the increase in cellult (3–6months) and old (24–31months) p53-tg andWTmice (youngWT, n=9, young
d-diastolic pressure; LV DevP, LV developed pressure. (b) Ca2+ transients and sarcomere
79 cells from±7mice). (c) Ca2+ transients and sarcomere shortening of cardiomyocytes
Fig. 2. p53, cardiomyocytes and CPCs. (a, b) Ki67-positive (a) and apoptotic TUNEL-positive (b) cardiomyocytes in young-adult, 8–11 months (WT: n= 9; p53-tg: n = 7), and old, 20–
25months (WT: n=6;p53-tg:n=8),WTandp53-tgmice. *p b 0.05 vs. young-adultWT; **p b 0.05 vs. oldWT; ***p b 0.05 vs. young-adult p53-tg. (c) p16INK4a-positive cardiomyocytes in
old, 18–33months, WT (n=4) and p53-tg (n=9)mice. (d, e) Number of c-kit-positive CPCs in atrial myocardium (d) and fraction of cycling Ki67-positive CPCs (e). WT: n=3; p53-tg:
n=4. (f) Population doubling time (PDT) inWT-CPCs (WT;n=3)and p53-tg-CPCs (p53-tg;n=3). (g) Fraction of Ki67 labeledWT-CPCs (n=3)andp53-tg-CPCs (n=3). (h) Fraction of
p16INK4a labeled WT-CPCs (n = 3) and p53-tg-CPCs (n = 3). (i) Apoptosis of WT-CPCs (n = 3) and p53-tg-CPCs (n = 3) measured by Annexin V assay. In all cases data are shown as
mean ± SD. *p b 0.05 vs. WT.
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ber of senescent p16INK4a-positive cardiomyocytes was comparable in
18–33 month-old WT and p53-tg (Fig. 2c), supporting the notion that
the extra copy of p53 did not promote myocardial aging. This finding
is typical of this model in which the p53 transgene is physiologically
regulated and it is not constitutively active. Conversely, transgenic and
mutant mice with chronically active p53 signaling are characterized
by shortened lifespan (Matheu et al., 2008).
Cardiomyocyte apoptosis and aging are controlled in part by the ex-
pression of the p53-dependent genes, Bax and Bcl2, and the p53-regu-
lated genes, angiotensinogen (Aogen) and angiotensin II (Ang II) type-
1 receptors (AT1R) (Leri et al., 1998, 1999; Dimmeler and Leri, 2008;
Xu et al., 2010). These parameters were measured in myocytes isolated
from p53-tg andWTmice at 25 months of age. At the protein level, the
quantity of the pro-apoptotic gene Bax and the anti-apoptotic gene Bcl2
was similar inWT and p53-tgmyocytes (Fig. S1). Additionally, the levels
of Aogen and AT1R did not differ in the two groups of cardiomyocytes
(Fig. S1). Thus, an extra copy of p53 has no negative effects on cardiac
performance, myocyte mechanics, Ca2+ transient, and cardiomyocyte
growth, senescence and death.3.2. p53 Preserves a Younger CPC Phenotype
CPC niches are preferentially located in the atrial myocardium
(Sanada et al., 2014) so that a quantitative analysis was performed in
this anatomical region of WT at 24–25 months and p53-tg at 24–
31 months. The frequency of CPCs was significantly higher in p53-tg,
while the fraction of replicating Ki67-positive CPCs was similar in the
two groups (Fig. 2d, e). Because of these two variables, a larger pool of
cycling CPCs was present in the atria of p53-tg mice.
To evaluate the growth reserve of CPCs, these cells were isolated
from the myocardium of p53-tg at 26–30 months and WT at 23–
25 months; cells were expanded in vitro and population doubling
time (PDT) was determined at P10-P13. PDT was 47% shorter in p53-
tg-CPCs than in WT-CPCs (Fig. 2f). Moreover, the percentage of Ki67-
positive CPCs at P10-P13 was 3.9-fold higher in p53-tg-CPCs (1528/
4561; 33.5%) than in WT-CPCs (543/6235; 8.7%) (Fig. 2g). At later pas-
sages, P16-P17, p16INK4a comprised 2.9% of WT-CPCs (36/1255; 2.9%)
and only 0.03% of p53-tg-CPCs (1/3275; 0.03%) (Fig. 2h). However, ap-
optosis was 35% higher in p53-tg-CPCs (Fig. 2i), despite the lower num-
ber of senescent cells. Thus, an extra copy of the p53 allele preserves a
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cumulation of senescent CPCs by potentiating cell death.
3.3. p53 Increases the Repair of DNA Damage in CPCs
Reactive oxygen species (ROS) induce foci of injury in the telomeric
and non-telomeric DNA; this affects the growth and viability of the tar-
get cells (Schieber and Chandel, 2014). To evaluate whether p53-tg-
CPCs had a superior, equal or inferior ability to sustain ROS-mediatedFig. 3. p53 improves the DDR of CPCs. (a) Nuclei from p53-tg-CPCs in the absence (Control) and
shown in these nuclei (green, right panels). Scale bar: 100 μm. (b) Fraction of γH2A.X-positive
(4284 cells from 3mice); Ctrl p53-tg-CPCs (13,334 cells from3mice); DoxoWT-CPCs (3958 cel
γH2A.X (green; left two panels) in nuclei of WT-CPCs and p53-tg-CPCs stained by DAPI (blue).
Imaris version 5.5.2 (right two panels). Scale bar: 5 μm. (d) Number of DDR foci counted in nu
were analyzed. (e) Nucleoids of WT-CPCs and p53-tg-CPCs are stained with Vista green dye (
damaged DNA in nuclei of WT-CPCs and p53-tg-CPCs at baseline (Control: WT, n = 62 come
comets from 3 mice; p53-tg, n = 61 comets from 3 mice). *p b 0.05 vs. WT Ctrl; **p b 0.05 vs.DNA damage than WT-CPCs, these stem cell classes were exposed to a
low dose of doxorubicin (Doxo) which is coupled with the formation
of DNA strand breaks (Goichberg et al., 2013).
The γH2A.X protein accumulates at regions of DNA strand breaks,
allowing the recognition of DNA damage (Mohrin et al., 2010;
Goichberg et al., 2013). The localization of γH2A.X increased from 4.7%
(200/4284; 4.7%) to 29% (1148/3958; 29%) in WT-CPCs and from 2.2%
(296/13334; 2.2%) to 73.8% (12,185/16496; 73.8%) in p53-tg-CPCs
(Fig. 3a, b). These results suggest that p53-tg-CPCs were 2.5-fold morein the presence of Doxo are stained by DAPI (blue, left panels); immunolabeled γH2A.X is
CPCs in the absence (control, Ctrl) and following exposure to Doxo (Doxo): Ctrl WT-CPCs
ls from 3mice); andDoxo p53-tg-CPCs (16,496 cells from 3mice). Data aremean± SD. (c)
DDR foci are illustrated in the same nuclei following three-dimensional reconstruction by
clei of WT-CPCs and p53-tg-CPCs. In each case, 24–59 γH2A.X positive nuclei from 3 mice
green, left panels). Comets are apparent after Doxo (green, right panels). (f) Quantity of
ts from 3 mice; p53-tg, n = 70 comets from 3 mice) and after Doxo (Doxo: WT, n = 76
Doxo WT-CPCs; ***p b 0.05 vs. p53-tg Ctrl.
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a process necessary for the initiation of DNA repair (Fumagalli et al.,
2012). However, the enhanced recruitment of γH2A.X at the sites of
DNA damage in p53-tg-CPCs may be independent from the extra copy
of the p53 allele; p53-tg-CPCs possess a younger cell phenotype (see
Fig. 2h, i), which may determine the higher efficiency of DNA repair in
this progenitor cell class.
DDR foci correspond to the localization of the γH2A.X protein at the
level of DNA lesions. In the presence of Doxo, the incidence of DDR foci
per nucleus (p53-tgCPCs, baseline: 6.3; WT-CPCs, baseline: 5.1; p53-
tgCPCs, Doxo: 79;WT-CPCs, Doxo: 63) increasedmarkedly and in a sim-
ilar manner, 12-fold, in p53-tg-CPCs andWT-CPCs (Fig. 3c, d), although
a larger fraction of p53-tg-CPCs recruited γH2A.X, as shown in Fig. 3b.
High values of DDR foci per nucleus may indicate an effective comple-
tion of DNA repair and/or a more extensive DNA damage (Lukas et al.,
2011). To test this possibility the degree of DNA damage in the two cat-
egories of CPCs was determined by the Comet assay (Lorenzo et al.,
2013).
CPCs were embedded in agarose on microscope slides and lysed to
form nucleoids. Electrophoresis was performed to identify structures
resembling comets at fluorescence microscopy (Fig. 3e). The fluores-
cence intensity of the tail (damaged DNA) relative to the head (intact
DNA) reflects the percentage of DNA damage; 61–76 comets were ana-
lyzed inWT-CPCs and p53-tg-CPCs in the absence andpresence of Doxo.
The distance between the center of the head and the center of the tail,
i.e. the tail moment length, indicates the frequency of DNA strand
breaks. The tail moment was calculated by the product of the percent-
age of damaged DNA and the tail moment length. The tail moment pro-
vides a parameter that comprises both the extent of DNA damage and
the frequency of DNA strand breaks; this index was found to be compa-
rable at baseline and to increase similarly in p53-tg-CPCs and WT-CPCs
following Doxo (Fig. 3f). Thus, the extent of damaged DNA promoted by
oxidative stress was analogous in the two CPC classes (see Fig. 3d), but a
larger fraction of cells carrying an extra copy of the p53 allele recruited
γH2A.X (see Fig. 3b), possibly enhancing DNA repair.
3.4. p53 Enhances the Expression of Genes Regulating DDR
The tumor suppressor p53 trans-activates several genes implicated
in the cell cycle and apoptosis (Riley et al., 2008), and an increase in
p53 gene dosagemay impact on the function of CPCs. Therefore, the ex-
pression of p53 and its target genes was measured in p53-tg-CPCs and
WT-CPCs in the absence and presence of Doxo. At baseline, the quantity
of p53was similar in the two stem cell categories (Fig. 4a–c). After 4 h of
Doxo, p53 levels increased and p53 phosphorylation at Ser-18, a post-
translational modification required for p53 DNA binding, was present
in both WT-CPCs and p53-tg-CPCs. At baseline, p53 phosphorylation
at Ser-34 was high in WT-CPCs and in p53-tg-CPCs and with Doxo de-
creased in both stem cell categories (Fig. 4b, c). Together with other
sites of post-translational modifications, phosphorylation of p53 at
Ser-34 is relevant to DDR (Loughery and Meek, 2013).
The expression of p53 and other genes (Riley et al., 2008) implicated
in inhibition of p53 activity (Mdm2), induction of apoptosis (Puma and
Noxa), protection from oxidative stress (Trp53inp), cellular senescence
(p16INK4a), cell cycle arrest and DNA repair (p21Cip1), and proliferation
(IGF-1 and PCNA), was measured by qRT-PCR. The expression of PIDD
was also determined; PIDD is a master regulator of cell fate decision,
playing a critical role in DNA repair, cell proliferation, survival and
death (Bock et al., 2012).
At baseline, p53, PIDD, IGF-1 and PCNA transcripts were higher and
p21Cip1 was lower in p53-tg-CPCs than in WT-CPCs, possibly reflecting
the enhanced proliferative activity of cells with an extra copy of the
p53 gene (Fig. 4d). With Doxo treatment, Mdm2, Puma and p21Cip1 in-
creased mostly in p53-tg-CPCs, suggesting that p21Cip1 promoted cell
cycle arrest and favored DNA repair. However, p16INK4a was decreased
in p53-tg-CPCs. PIDD and Trp53inp were upregulated in p53-tg-CPCsand WT-CPCs, but the changes in Trp53inp were greater in p53-tg-
CPCs; thus, the protection from oxidative stress was enhanced in p53-
tg-CPCs (Fig. 4d). With Doxo, the expression of IGF-1 and PCNA de-
creased in p53-tg-CPCs and these changes are consistentwith activation
of the DNA repair process. In WT-CPCs, Doxo led to an attenuation of
IGF-1 and an upregulation of Noxa, which may mediate cell apoptosis.
The temporal changes in the expression of p53, Mdm2, p21Cip1,
Noxa, PIDD, Trp53inp and Puma were evaluated in p53-tg-CPCs and
WT-CPCs from time 0 to 120 min following Doxo-treatment (Fig. S2).
In p53-tg-CPCs, the expression of p53 appeared to increase earlier
than the upregulation of Mdm2, p21Cip1, PIDD, Trp53inp and Puma.
These adaptations suggest that oxidative stress was coupled with a
rapid response in the genesmodulating p53 function, growth arrest, ox-
idative DNA damage and repair, and cell death. Conversely, inWT-CPCs,
the modest increase in p53 was associated with a time-dependent in-
crease in the pro-apoptotic gene Noxa (Fig. S2).
The expression of Noxa and Puma is essential for p53-mediated ap-
optosis; in this regard, the deletion of these two genes prevents cell
death in response to stimuli leading to upregulation of p53 activity
(Valente et al., 2013). The differential expression of Noxa and Puma in
WT-CPCs and p53-tg-CPCswith oxidative stressmay depend on the dis-
tinct post-translational modifications of p53, which condition the
transactivation of specific target genes. Additionally, γH2A.X, which is
more effectively recruited at the sites of DNA damage in p53-tg-CPCs,
promotes upregulation of Puma independently from p53 signaling (Xu
et al., 2016). Thus, p53 is a critical determinant of stem cell fate and an
extra copy of the p53 allele positively impacts on the survival and
growth of CPCs.
3.5. p53 Promotes DNA Repair and Recovery of CPC Growth
To determine whether the distinct response of CPC classes to oxida-
tive stress was translated in a differential recovery in function, p53-tg-
CPCs and WT-CPCs were exposed to Doxo for 4 h (Doxo-pulse) and,
after Doxo removal, cellular senescence, DNA repair and proliferation
were measured following a 72-hour recovery period (Recovery). After
recovery, p16INK4a expression was barely detectable by Western blot-
ting in p53-tg-CPCs, but was upregulated inWT-CPCs (Fig. 5a). Similar-
ly, by immunolabeling and confocal microscopy, a small fraction of
p16INK4a-positive cells was identified in p53-tg-CPCs, while numerous
WT-CPCs expressed p16INK4a [Fig. 5b; (WT-CPCs: control = 6/610,
0.98%; Doxo pulse = 22/1742, 1.26%; Recovery = 150/2877, 5.2%)
(p53-tg-CPCs: control = 6/1903, 0.3.2%; Doxo pulse = 3/4293, 0.07%;
Recovery = 32/3473, 0.9%)]. Importantly, following recovery, the num-
ber of DDR foci and the tail moment decreased dramatically in p53-tg-
CPCs; however, these parameters remained high in WT-CPCs (Fig. 5c–
e). Additionally, a progressive increase in cell proliferation was ob-
served in p53-tg-CPCs from 24 to 48 and 72 h after the removal of
Doxo [Fig. 5f; (WT-CPCs: 24 h = 143/8167, 1.7%; 48 h = 511/8405,
6.1%; 72 h = 270/4915, 5.4%) (p53-tg-CPCs: 24 h = 305/7902, 0.3.9%;
48 h = 1443/13635, 11%; 72 h = 1032/6246, 17%)]. In contrast, the
reinstitution of cell proliferation was modest in WT-CPCs. Thus, follow-
ing oxidative stress, an extra copy of the p53 allele potentiates the abil-
ity of CPCs to reestablish the integrity of the DNA, leading to a relevant
restoration of cell growth.
3.6. p53 Increases the Engraftment of CPCs in the Diabetic Heart
The in vitro results discussed thus far have suggested that p53-tg-
CPCs have the capacity to grow extensively in vitro and are more resis-
tant to ROS than WT-CPCs. These two characteristics are critical for the
successful implementation of cell therapy for the pathologic heart. Tis-
sue reconstitution involves isolation, in vitro expansion and delivery
of CPCs to the damaged myocardium, where the hostile environment
and high levels of oxidative stress (Kizil et al., 2015) interfere with the
cardiac repair process and cardiomyocyte regeneration (Broughton
Fig. 4. p53 and p53-dependent genes. (a) Quantity of p53 protein by automatedWesWestern blotting inWT-CPCs (WT) and p53-tg-CPCs (p53-tg) at baseline (blue line) and after Doxo
(red line). Tracings illustrate the peak level of p53 in the four CPC classes; n=3 in all cases. (b) The pseudo-blots show the expression of phosphorylated p53 at Ser-18 and Ser-34, and p53
and GAPDH in the four CPC classes. (c) Quantitative data are shown asmean± SD. *p b 0.05 vs. WT Ctrl. **p b 0.05 vs. WT Doxo. ***p b 0.05 vs. p53-tg Ctrl. (d)mRNA level of p53 and p53
regulated genes in the CPC classes at baseline (Ctrl) and after Doxo; n = 3 in all cases. Ct values above 35 cycles were considered not detectable. For statistics see panel B.
231R. Kannappan et al. / EBioMedicine 16 (2017) 224–237and Sussman, 2016). To test whether p53-tg-CPCs retained in vivo the
properties documented in vitro, both WT-CPCs and p53-tg-CPCs were
injected intramyocardially in diabetic mice 3–4 weeks after the admin-
istration of streptozotocin when the blood glucose level was
N400 mg/dl. This model was selected because is characterized by en-
hanced oxygen toxicity (Rota et al., 2006). Animals, 4 in each group,
were sacrificed 3 days later when engraftment of CPCs is expected to
be completed and cell differentiation may begin to occur. This protocol
was based on previous observations concerning the engraftment andlineage specification of c-kit-positive hematopoietic stemcells delivered
to the damagedmyocardium (Rota et al., 2007). Four injections of EGFP-
labeled CPCs were performed in different sites of the LV wall. Diabetes
was characterized by foci of tissue injury where both WT-CPCs and
p53-tg-CPCs homed (Fig. 6; Fig. S3) and began to acquire the cardio-
myocyte phenotype (Fig. 7a–d). Quantitatively, the number of EGFP-
positive cells in the LV myocardium was 2350/10 mm2 and 1590/
10 mm2 in diabetic mice treated with p53-tg-CPCs and WT-CPCs, re-
spectively (Fig. 7e).
Fig. 5. p53 favors the functional recovery of CPCs from oxidative stress in vitro. (a)Western blotting of p16INK4a at baseline, after Doxo-pulse and following recovery ofWT-CPCs (WT) and
p53-tg-CPCs (p53-tg); n = 3 in all cases. Optical density data are mean ± SD. *p b 0.05 vs. WT-Control. **p b 0.05 vs. WT-Doxo-pulse. ***p b 0.05 vs. WT-recovery. (b) p16INK4a labeling
(upper left panel, yellow) of WT-CPCs exposed to Doxo. Nuclei are stained by DAPI (upper right panel, blue). Phalloidin (lower left panel, white). Merge of p16INK4a, DAPI and phalloidin
(lower right panel). Scale bar, 50 μm. Fraction of p16INK4a-positiveWT-CPCs and p53-tg-CPCs at baseline, following Doxo-pulse and after recovery; n=3 in all cases. Data aremean± SD.
*p b 0.05 vs. WT-Control. **p b 0.05 vs. WT-Doxo-pulse. ***p b 0.05 vs. WT recovery. †p b 0.05 vs. p53-tg control. ‡p b 0.05 vs. p53-tg Doxo-pulse. (c) Number of DDR foci inWT-CPCs and
p53-tg-CPCs at baseline, after Doxo-pulse and following recovery; n=3 in all cases. For statistics see panel B. (d) Nucleoids inWT-CPCs and p53-tg-CPCs at baseline, followingDoxo-pulse
and after recovery are stainedwith Vista green dye (green). Comets are apparent inDoxo-pulse and after recovery ofWT-CPCs, while intact DNA is noted in p53-tg-CPCs after recovery. (e)
Damaged DNA in nuclei of WT-CPCs and p53-tg-CPCs at baseline, after Doxo-pulse and following recovery; n= 3 in all cases. For statistics see panel B. (f) Fraction of Ki67-positive WT-
CPCs and p53-tg-CPCs following 24, 48 and 72 h recovery period; n = 3 in all cases.*p b 0.05 vs. 24 h. **p b 0.05 vs. 48 h.
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myocyte commitment were recognized by the expression of the tran-
scription factor GATA4 (Fig. 8; Fig. S4). The volume of these developing
myocytes can be expected to increase with time and reach in part anadult cell phenotype, as observed previously by in situ activation of en-
dogenous CPCs after myocardial infarction. Importantly, the generation
of parenchymal cells in that setting was associated with growth of both
resistance arterioles and capillary profiles (Urbanek et al., 2005). Thus,
Fig. 6.p53-tg-CPCs engraft in thediabetic heart. (a, b)Areas ofmyocardial damage (*) in the LVwall; EGFP-positive (green) p53-tg-CPCs are engrafted in themajority of these foci of injury.
Cardiomyocytes are labeled by α-sarcomeric actin (α-SA; red).
233R. Kannappan et al. / EBioMedicine 16 (2017) 224–237CPCs carrying an extra copy of the p53 gene have an intrinsic advantage
and a superior cellular regenerative response after injection in the dia-
betic heart.
4. Discussion
The results of the current study indicate that CPCs obtained from the
heart of old mice carrying an extra gene-dose of p53 can be propagated
extensively in vitro retaining an impressive growth reserve at late pas-
sages. Based on this geneticmodification, large quantities of CPCs can be
generated, raising the possibility thatmultiple temporally distinct deliv-
eries of cells can be introduced to restore the structural and functional
integrity of the damagedmyocardium. This critical aspect of autologous
cell therapy has recently been documented experimentally (Tokita et
al., 2016). Although it might be intuitively obvious that one injection
of CPCs cannot reverse cardiac pathology, thiswork has provided the in-
formation needed for the development of a better strategy for the treat-
ment of human heart failure. Thus, a large number of the patient's own
CPCs is required, together with the ability of the expanded cells to en-
graft within the unfavorable environment of the diseased heart.
As documented in the current study, the enhanced expression of p53
leads to a complex cellular response which involves a network of genes
implicated in DNA repair and cell proliferation, and cellular senescence
and apoptosis (Fig. S5). The extra copy of the p53 gene improves the
ability of CPCs to sustain oxidative stress, an adaptation mediated by a
rapid restoration of the integrity of the DNA and cell division. The
prompt and efficient recruitment of DDR proteins at the sites of DNA
strand breaks in p53-tg-CPCs reflects the mechanism needed to coun-
teract the consequences of DNA damaging agents, typically present inthe diabetic, old and failing heart (Frustaci et al., 2000; Dimmeler and
Leri, 2008; Goichberg et al., 2014). Conversely, CPCs with unmodified
quantity of endogenous p53 are less resistant to oxidative stress and
fail to mend proficiently DNA strand breaks, a defect that results in irre-
versible growth arrest and cell death. Thus, p53-tg-CPCs have a signifi-
cant biological and therapeutic advantage with respect to WT-CPCs;
they manifest a higher survival rate when delivered in vivo enhancing
cell homing and potentially myocardial regeneration. The increased
dosage of p53 provides CPCs with critical defense mechanisms neces-
sary for the cells to remain viable in the adverse milieu of the diabetic
and failing heart.
Despite severe hyperglycemia and its toxic consequences, p53-tg-
CPCs engraft more effectively thanWT-CPCs within the sites of damage
present throughout the myocardium of diabetic mice and initiate a re-
parative process. The difference in the magnitude of cell homing ob-
served with WT-CPCs and p53-tg-CPCs in the presence of diabetes
underscores how critical is the function of p53 in enhancing the ability
of the delivered cells to colonize the injured ventricle, a condition neces-
sary for the successful replacement of cardiomyocytes lost as a result of
cardiac pathology (Leri et al., 2015).
Human CPCs have recently been introduced in the management of
heart failure in patients suffering from post-infarction ischemic cardio-
myopathy with encouraging results (Chugh et al., 2012; Makkar et al.,
2012). However, several clinical trials with a variety of progenitor cells
have been performed in the last decade in similar patient cohorts but
the outcome has been inconsistent (Afzal et al., 2015). Despite the use
of large number of cells, there is general agreement that the fraction
of engrafted cells is miniscule and this limitation precludes an efficient
recovery of the injured myocardium. The strategy employed here may
234 R. Kannappan et al. / EBioMedicine 16 (2017) 224–237overcome in part this problem and make stem cell therapy more effec-
tive in restoring the structural and functional integrity of the decom-
pensated human heart.
Poor survival and limited retention of adoptively transferred stem
cells in the pathologic heart may reduce significantly the efficacy of re-
generative therapy. Stemcell viability is influenced by the ischemic con-
dition and inflammatory response of the recipient myocardium and the
intrinsic properties of donor cells (Broughton and Sussman, 2016). Sev-
eral strategies have been utilized to reduce the susceptibility of the de-
livered cells to die and prolong the window of time available for their
engraftment within the damaged myocardium. Preconditioning of
CPCswith a variety of cytokines potentiates their resistance to oxidative
stress, favoring their migration and recruitment.
A more prolonged effect is obtained when stem cells are genetically
modified to express anti-apoptotic mediators. Canonical regulators of
myocyte survival, oncogenic proteins and factors involved in the devel-
opment of embryonic-fetal myocyte progenitors have been employed
(Broughton and Sussman, 2016). The serine/threonine Pim-1 kinase
which is a downstream target of Akt favors the engraftment and lineage
commitment of CPCs and long-term myocardial regeneration (Cottage
et al., 2012; Mohsin et al., 2013). CPCs obtained by p53-tg mice show
characteristics similar to those observed in the presence of Pim-1: the
increased proliferation and delayed cell aging in vitro are accompanied
by enhanced engraftment and survival in vivo. The extra gene copy of
p53, however, provides an additional advantage through the selective
depletion of old damaged stem cells maintaining a pool of progenitors
with a younger cell phenotype.
The structural integration of the delivered CPCs with the recipient
organ is the primary event that conditions the long-term recovery of
the lost myocardium. However, in the current study, we did not evalu-
ate the durability of the process, which will be determined in future
work with the expectation that the injected p53-tg-CPCswill differenti-
ate and generate mature, functionally-competent cardiomyocytes, to-
gether with the required coronary microcirculation. At the early time
point, the injected WT-CPCs and p53-tg-CPCs were restricted to the in-
jured regions of the ventricularwall. Themicroenvironment of the dam-
aged diabetic myocardium is unquestionably hostile although
obligatory for cell homing. The transplantation of progenitor cells in
the intact tissue results in cell apoptosis (Tillmanns et al., 2008).
The function of p53 as fate modulator has been studied in several
stem cell systems, where it exerts opposite functions, which appear to
be context and cell type dependent. p53 orchestrates the polarity of
self-renewing divisions in neural stem cells and coordinates the timing
for cell fate specification (Quadrato and Di Giovanni, 2012). During
steady-state hematopoiesis, the basal-level of p53 activity regulates
the quiescence and self-renewal of hematopoietic stem cells (HSCs)
expanding the immature cell pool (Liu et al., 2009a). This phenomenon
may overcome the decline in HSC function observed with aging, al-
though a larger pool of HSCs with intense self-renewal capacity may
favor the development of leukemia (Asai et al., 2011).
The ability of the heart to maintain the steady state and respond to
injury declineswith aging anddiabetes (Eming et al., 2014). The compo-
sition of the stem cell pool changes in both cases, favoring the accumu-
lation of cells that do not self-renew andmaymanifest a skewedpattern
of lineage choices. Apoptosis is restricted to p16INK4a-positive CPCs, but
the process of clearance of old CPCs is inefficient resulting in their pro-
gressive accumulation (Sanada et al., 2014). Enhanced p53 expression
corrects the abnormal behavior of CPCs, modifying their fate. As
shown here, in the presence of oxidative stress, p53 upregulates theFig. 7. p53 expands the engraftment of CPCswithin the diabetic myocardium. (a–d) Areas
of myocardial regeneration shown at different magnification contain small developing
cardiomyocytes, which express EGFP and α-SA (yellow; arrows). (e) Number of EGFP-
positive cells per 10 mm2 of myocardium in diabetic hearts injected with WT-CPCs
(n = 4) or p53-tg-CPCs (n = 4). Data are mean ± SD. *p b 0.05 vs. WT-CPCs.
Fig. 8.Early commitment of p53-tg-CPCs. (a-c) GATA4 is expressed (left, white) in EGFP-positive cells (right, green) distributedwithin thedamageddiabeticmyocardium. Cardiomyocytes
are labeled by troponin I (right, TnI: red).
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ly, p53 increases the level of Puma favoring apoptosis of damaged CPCs.
Thus, p53, through cell death activation, prevents the secretory activity
of senescent CPCs which release a variety of molecules exerting pro-
aging effects on the surrounding young cells (Tchkonia et al., 2013).
Stem cells constitute a long-lived replicative cell population that ex-
periences prolonged periods of quiescence. Stem cell quiescence pro-
tects from endogenous stresses mediated by cell respiration and DNA
division, but these functions are attenuated by oxidative stress. Old,
rarely dividing cells show more γH2AX foci than actively proliferating
cells (Rossi et al., 2007; Liu et al., 2009b), since the molecular control
of DNA repair is intimately linked to the progression of the cell cycle. Im-
portantly, the extent of DNA damage is comparable in WT-CPCs andp53-tg-CPCs but the enhanced expression of p53 expands the pool of
cells displaying DDR foci. This biological response supports the view
that CPCs genetically modified to express physiologically regulated
p53 are protected from environmental stimuli and genomic lesions.
DNA repair maintains genomic integrity and attenuates the rate of
aging of p53-tg-CPCs.
Whether the enhanced expression of p53 improves the intrinsic
properties of CPCs, or the intact resident stem cell compartment is acti-
vated by the intramyocardial injection of specific growth factors, these
cells are responsible for myocyte and coronary vessel regeneration
(Beltrami et al., 2003; Sanada et al., 2014; Liu et al., 2015). The replica-
tive reserve of c-kit-positive CPCs predicts the evolution of ischemic car-
diomyopathy following revascularization in humans (D'Amario et al.,
236 R. Kannappan et al. / EBioMedicine 16 (2017) 224–2372014) and profound defects in human CPC function are presentwith ad-
vanced heart failure (Urbanek et al., 2003, 2005) and in the decompen-
sated senescent human heart (Chimenti et al., 2003). CPCs are the
critical determinant of human cardiac pathology and strategies increas-
ing their growth and reparative process may have important clinical
implications.
These experimental results cannot be translated to human beings
without caveats. Mouse CPCs differ fromhuman CPCs. The latter are iso-
lated from small samples of diseased myocardium although intact CPCs
with maintained growth reserve have always been found (D'Amario et
al., 2011).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.01.028.
Funding Sources
This work was supported by grants from the National Institutes of
Health (NIH) (P01-AG023071) and by Cardiocentro Ticino Foundation
(R01AG37490). Our funding sources played no role in how the research
was conducted.
Conflict of Interest
P.A. is a member of Autologous LLC and AAL Scientifics Inc. A.L. is a
member of AAL Scientifics Inc. The other authors did not report any con-
flict of interest.
Author Contributions
R.K. andA.M. designed and conducted the experiments, analyzed the
data and participated in the writing of the manuscript; J.F-M., E.Z., G.P.,
A.C., M. C. C-D-S., A. B-C., F.S., N.I. prepared reagents and conducted the
experiments; M.R. prepared reagents and conducted experiments and
analyzed part the data; M.A.B., M.S., participated in the discussion of
the study and critically reviewed the manuscript; P.A. analyzed the
data and participated in the writing of the manuscript; A.L. designed
the experiments, analyzed the data and wrote the manuscript.
All co-authors reviewed critically the manuscript and gave final ap-




Afzal, M.R., Samanta, A., Shah, Z.I., Jeevanantham, V., Abdel-Latif, A., Zuba-Surma, E.K.,
Dawn, B., 2015. Adult bone marrow cell therapy for ischemic heart disease: evidence
and insights from randomized controlled trials. Circ. Res. 117, 558–575.
Asai, T., Liu, Y., Bae, N., Nimer, S.D., 2011. The p53 tumor suppressor protein regulates he-
matopoietic stem cell fate. J. Cell. Physiol. 226, 2215–2221.
Beausejour, C.M., Campisi, J., 2006. Ageing: balancing regeneration and cancer. Nature
443, 404–405.
Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H.,
Rota, M., Musso, E., Urbanek, K., et al., 2003. Adult cardiac stem cells are multipotent
and support myocardial regeneration. Cell 114, 763–776.
Bock, F.J., Peintner, L., Tanzer, M., Manzl, C., Villunger, A., 2012. P53-induced protein with
a death domain (PIDD): master of puppets? Oncogene 31, 4733–4739.
Broughton, K.M., Sussman, M.A., 2016. Empowering adult stem cells for myocardial re-
generation v2.0: success in small steps. Circ. Res. 118, 867–880.
Cheng, Z., Ito, S., Nishio, N., Thanasegaran, S., Fang, H., Isobe, K., 2013. Characteristics of
cardiac aging in C57BL/6 mice. Exp. Gerontol. 48, 341–348.
Chimenti, C., Kajstura, J., Torella, D., Urbanek, K., Heleniak, H., Colussi, C., Di Meglio, F.,
Nadal-Ginard, B., Frustaci, A., Leri, A., et al., 2003. Senescence and death of primitive
cells and myocytes lead to premature cardiac aging and heart failure. Circ. Res. 93,
604–613.
Chugh, A.R., Beache, G.M., Loughran, J.H., Mewton, N., Elmore, J.B., Kajstura, J., Pappas, P.,
Tatooles, A., Stoddard, M.F., Lima, J.A., et al., 2012. Administration of cardiac stem
cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects
and interim analysis of myocardial function and viability by magnetic resonance. Cir-
culation 126, S54–S64.Cottage, C.T., Neidig, L., Sundararaman, B., Din, S., Joyo, A.Y., Bailey, B., Gude, N., Hariharan,
N., Sussman, M.A., 2012. Increased mitotic rate coincident with transient telomere
lengthening resulting from pim-1 overexpression in cardiac progenitor cells. Stem
Cells 30, 2512–2522.
D'Amario, D., Fiorini, C., Campbell, P.M., Goichberg, P., Sanada, F., Zheng, H., Hosoda, T.,
Rota, M., Connell, J.M., et al., 2011. Functionally competent cardiac stem cells can be
isolated from endomyocardial biopsies of patients with advanced cardiomyopathies.
Circ. Res. 108, 857–861.
D'Amario, D., Leone, A.M., Iaconelli, A., Luciani, M., Gaudino, M., Kannappan, R., Manchi,
M., Severino, A., Shin, S.H., Graziani, F., et al., 2014. Growth properties of cardiac
stem cells are a novel biomarker of patients' outcome after coronary bypass surgery.
Circulation 129, 157–172.
Dimmeler, S., Leri, A., 2008. Aging and disease as modifiers of efficacy of cell therapy. Circ.
Res. 102, 1319–1330.
Eming, S.A., Martin, P., Tomic-Canic, M., 2014. Wound repair and regeneration: mecha-
nisms, signaling, and translation. Sci. Transl. Med. 6 (265sr6).
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B.,
Anversa, P., 2000. Myocardial cell death in human diabetes. Circ. Res. 87, 1123–1132.
Fumagalli, M., Rossiello, F., Clerici, M., Barozzi, S., Cittaro, D., Kaplunov, J.M., Bucci, G.,
Dobreva, M., Matti, V., Beausejour, C.M., et al., 2012. Telomeric DNA damage is irrep-
arable and causes persistent DNA-damage-response activation. Nat. Cell Biol. 14,
355–365.
Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., Weill,
J.C., Blasco, M.A., Serrano, M., 2002. “Super p53”mice exhibit enhanced DNA damage
response, are tumor resistant and age normally. EMBO J. 21, 6225–6235.
Garcia-Cao, I., Garcia-Cao, M., Tomas-Loba, A., Martin-Caballero, J., Flores, J.M., Klatt, P.,
Blasco, M.A., Serrano, M., 2006. Increased p53 activity does not accelerate telomere-
driven ageing. EMBO Rep. 7, 546–552.
Goichberg, P., Kannappan, R., Cimini, M., Bai, Y., Sanada, F., Sorrentino, A., Signore, S.,
Kajstura, J., Rota, M., Anversa, P., et al., 2013. Age-associated defects in EphA2 signal-
ing impair the migration of human cardiac progenitor cells. Circulation 128,
2211–2223.
Goichberg, P., Chang, J., Liao, R., Leri, A., 2014. Cardiac stem cells: biology and clinical ap-
plications. Antioxid. Redox Signal. 21, 2002–2017.
Hachamovitch, R., Wicker, P., Capasso, J.M., Anversa, P., 1989. Alterations of coronary
blood flow and reserve with aging in Fischer 344 rats. Am. J. Phys. 256, H66–H73.
Harris, V.M., 2015. Protein detection by simpleWestern analysis. MethodsMol. Biol. 1312,
465–468.
Hosoda, T., D'Amario, D., Cabral-Da-Silva, M.C., Zheng, H., Padin-Iruegas, M.E., Ogorek, B.,
Ferreira-Martins, J., Yasuzawa-Amano, S., Amano, K., Ide-Iwata, N., 2009. Clonality of
mouse and human cardiomyogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 106,
17169–17174.
Kizil, C., Kyritsis, N., Brand, M., 2015. Effects of inflammation on stem cells: together they
strive? EMBO Rep. 16, 416–426.
Leri, A., Claudio, P.P., Li, Q., Wang, X., Reiss, K., Wang, S., Malhotra, A., Kajstura, J., Anversa,
P., 1998. Stretch-mediated release of angiotensin II induces myocyte apoptosis by ac-
tivating p53 that enhances the local renin-angiotensin system and decreases the Bcl-
2-to-Bax protein ratio in the cell. J. Clin. Invest. 101, 1326–1342.
Leri, A., Liu, Y., Wang, X., Kajstura, J., Malhotra, A., Meggs, L.G., Anversa, P., 1999. Overex-
pression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin
system in transgenic mice. Circ. Res. 84, 752–762.
Leri, A., Franco, S., Zacheo, A., Barlucchi, L., Chimenti, S., Limana, F., Nadal-Ginard, B.,
Kajstura, J., Anversa, P., Blasco, M.A., 2003. Ablation of telomerase and telomere loss
leads to cardiac dilatation and heart failure associated with p53 upregulation.
EMBO J. 22, 131–139.
Leri, A., Rota, M., Pasqualini, F.S., Goichberg, P., Anversa, P., 2015. Origin of cardiomyocytes
in the adult heart. Circ. Res. 116, 150–166.
Liu, Y., Elf, S.E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S., Lee, J.M.,
Deblasio, A., Menendez, S., et al., 2009a. p53 regulates hematopoietic stem cell quies-
cence. Cell Stem Cell 4, 37–48.
Liu, Y., Elf, S.E., Asai, T., Miyata, Y., Liu, Y., Sashida, G., Huang, G., Di Giandomenico, S., Koff,
A., Nimer, S.D., 2009b. The p53 tumor suppressor protein is a critical regulator of he-
matopoietic stem cell behavior. Cell Cycle 8, 3120–3124.
Liu, X., Hall, S.R., Wang, Z., Huang, H., Ghanta, S., Di Sante, M., Leri, A., Anversa, P., Perrella,
M., 2015. Rescue of neonatal cardiac dysfunction in mice by administration of cardiac
progenitor cells in utero. Nat. Commun. 6, 8825.
Lorenzo, Y., Costa, S., Collins, A.R., Azqueta, A., 2013. The comet assay, DNA damage, DNA
repair and cytotoxicity: hedgehogs are not always dead. Mutagenesis 28, 427–432.
Loughery, J., Meek, D., 2013. Switching on p53: an essential role for protein phosphoryla-
tion? BioDiscovery 8, 1.
Lukas, J., Lukas, C., Bartek, J., 2011. More than just a focus: the chromatin response to DNA
damage and its role in genome integrity maintenance. Nat. Cell Biol. 13, 1161–1169.
Makkar, R.R., Smith, R.R., Cheng, K., Malliaras, K., Thomson, L.E., Berman, D., Czer, L.S.,
Marban, L., Mendizabal, A., Johnston, P.V., et al., 2012. Intracoronary cardiosphere-de-
rived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospec-
tive, randomised phase 1 trial. Lancet 379, 895–904.
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J.M., Viña, J.,
Blasco, M.A., Serrano, M., 2007. Delayed ageing through damage protection by the
Arf/p53 pathway. Nature 448, 375–379.
Matheu, A., Maraver, A., Serrano, M., 2008. The Arf/p53 pathway in cancer and aging. Can-
cer Res. 68, 6031–6034.
McDonald, J.H., 2014. Handbook of Biological Statistics. third ed. Sparky House Publishing,
Baltimore, Maryland.
Mohrin, M., Bourke, E., Alexander, D., Warr, M.R., Barry-Holson, K., Le Beau, M.M.,
Morrison, C.G., Passegue, E., 2010. Hematopoietic stem cell quiescence promotes
error-prone DNA repair and mutagenesis. Cell Stem Cell 7, 174–185.
237R. Kannappan et al. / EBioMedicine 16 (2017) 224–237Mohsin, S., Khan, M., Nguyen, J., Alkatib, M., Siddiqi, S., Hariharan, N., Wallach, K.,
Monsanto, M., Gude, N., Dembitsky, W., et al., 2013. Rejuvenation of human cardiac
progenitor cells with Pim-1 kinase. Circ. Res. 113, 1169–1179.
Quadrato, G., Di Giovanni, S., 2012. Gatekeeper between quiescence and differentiation:
p53 in axonal outgrowth and neurogenesis. Int. Rev. Neurobiol. 105, 71–89.
Riley, T., Sontag, E., Chen, P., Levine, A., 2008. Transcriptional control of human p53-regu-
lated genes. Nat. Rev. Mol. Cell. Biol. 9, 402–412.
Rossi, D.J., Seita, J., Czechowicz, A., Bhattacharya, D., Bryder, D., Weissman, I.L., 2007. He-
matopoietic stem cell quiescence attenuates DNA damage response and permits
DNA damage accumulation during aging. Cell Cycle 6, 2371–2376.
Rota, M., LeCapitaine, N., Hosoda, T., Boni, A., De Angelis, A., Padin-Iruegas, M.E., Esposito,
G., Vitale, S., Urbanek, K., Casarsa, C., et al., 2006. Diabetes promotes cardiac stem cell
aging and heart failure, which are prevented by deletion of the p66shc gene. Circ. Res.
99, 42–52.
Rota, M., Kajstura, J., Hosoda, T., Bearzi, C., Vitale, S., Esposito, G., Iaffaldano, G., Padin-
Iruegas, M.E., Gonzalez, A., Rizzi, R., et al., 2007. Bone marrow cells adopt the
cardiomyogenic fate in vivo. Proc. Natl. Acad. Sci. U. S. A. 104, 17783–17788.
Sanada, F., Kim, J., Czarna, A., Chan, N.Y., Signore, S., Ogorek, B., Isobe, K., Wybieralska, E.,
Borghetti, G., Pesapane, A., et al., 2014. c-kit-positive cardiac stem cells nested in hyp-
oxic niches are activated by stem cell factor reversing the aging myopathy. Circ. Res.
114, 41–55.
Schieber, M., Chandel, N.S., 2014. ROS function in redox signaling and oxidative stress.
Curr. Biol. 24, R453–R462.
Serrano, M., Blasco, M.A., 2007. Cancer and ageing: convergent and divergent mecha-
nisms. Nat. Rev. Mol. Cell. Biol. 8, 715–722.
Signore, S., Sorrentino, A., Borghetti, G., Cannata, A., Meo, M., Zhou, Y., Kannappan, R.,
Pasqualini, F., O'Malley, H., Sundman, M., et al., 2015. Late Na (+) current and
protracted electrical recovery are critical determinants of the aging myopathy. Nat.
Commun. 6, 8803.
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., Kirkland, J.L., 2013. Cellular senescence
and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest.
123, 966–972.Tillmanns, J., Rota, M., Hosoda, T., Misao, Y., Esposito, G., Gonzalez, A., Vitale, S., Parolin, C.,
Yasuzawa-Amano, S., Muraski, J., et al., 2008. Formation of large coronary arteries by
cardiac progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 105, 1668–1673.
Tokita, Y., Tang, X.L., Li, Q., Wysoczynski, M., Hong, K.U., Nakamura, S., Wu,W.J., Xie,W., Li,
D., Hunt, G., et al., 2016. Repeated administrations of cardiac progenitor cells are
markedly more effective than a single administration: a new paradigm in cell thera-
py. Circ. Res. 119, 635–651.
Torella, D., Rota, M., Nurzynska, D., Musso, E., Monsen, A., Shiraishi, I., Zias, E., Walsh, K.,
Rosenzweig, A., Sussman, M.A., et al., 2004. Cardiac stem cell and myocyte aging,
heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. 94, 514–524.
Urbanek, K., Quaini, F., Tasca, G., Torella, D., Castaldo, C., Nadal-Ginard, B., Leri, A., Kajstura,
J., Quaini, E., Anversa, P., 2003. Intense myocyte formation from cardiac stem cells in
human cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100, 10440–10445.
Urbanek, K., Torella, D., Sheikh, F., De Angelis, A., Nurzynska, D., Silvestri, F., Beltrami, C.A.,
Bussani, R., Beltrami, A.P., Quaini, F., et al., 2005. Myocardial regeneration by activa-
tion of multipotent cardiac stem cells in ischemic heart failure. Proc. Natl. Acad. Sci.
U. S. A. 102, 8692–8697.
Valente, L.J., Gray, D.H., Michalak, E.M., Pinon-Hofbauer, J., Egle, A., Scott, C.L., Janic, A.,
Strasser, A., 2013. p53 efficiently suppresses tumor development in the complete ab-
sence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell
Rep. 3, 1339–1345.
Xu, J., Carretero, O.A., Liao, T.D., Peng, H., Shesely, E.G., Xu, J., Liu, T.S., Yang, J.J.,
Reudelhuber, T.L., Yang, X.P., 2010. Local angiotensin II aggravates cardiac remodeling
in hypertension. Am. J. Physiol. Heart Circ. Physiol. 299, H1328–H1338.
Xu, C., Zhang, L., Duan, L., Lu, C., 2016. MicroRNA-3196 is inhibited by H2AX phosphory-
lation and attenuates lung cancer cell apoptosis by downregulating PUMA.
Oncotarget 7, 77764–77776.
